Pred-Forte

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pred-Forte

Property Description
Active ingredient Prednisolone Acetate
Form Ophthalmic Suspension (Eye Drops)
Pharmacological class Ophthalmic Corticosteroid / Glucocorticoid
General purpose Suppression of ocular inflammation (swelling, redness, irritation)
Origin Synthetic Steroid

What is Pred-Forte and Its Pharmacological Class?

The product known by the trade name Pred-Forte is a specialized, prescription-only medication. Its active component is Prednisolone Acetate, and it is classified pharmacologically as an ophthalmic corticosteroid, a potent type of synthetic glucocorticoid. This agent is primarily designed as a powerful steroidal anti-inflammatory drug for direct, topical ophthalmic use. Prednisolone is a highly potent corticosteroid used to manage serious inflammatory and allergic conditions of the eye.

Composition and Physical Form: A Microfine Ophthalmic Suspension

The formulation is characterized as a single-ingredient product, containing only the Prednisolone Acetate active substance, which is entirely synthetic in origin. The medication is presented as an ophthalmic suspension, which is a sterile liquid preparation containing fine, solid particles of the active drug dispersed within an aqueous vehicle. This specific presentation, often noted as a microfine suspension, is a distinguishing feature, as it is engineered to maximize the duration the Prednisolone Acetate remains in contact with the eye's surface, enhancing its localized therapeutic availability compared to simple solutions.

The General Purpose of Prednisolone Acetate

The general function of this powerful ophthalmic corticosteroid is to achieve a rapid and effective reduction of inflammation-related signs, displaying significant anti-inflammatory potency. By interacting as a glucocorticoid receptor agonist, the drug swiftly addresses the common and intense manifestations of inflammation, such as severe swelling, redness, and related irritation. Its high-level purpose is to stabilize and protect delicate ocular tissues from the damaging, unchecked consequences of chronic or acute non-infectious allergic and inflammatory events.

What side effects are possible with Pred-Forte?

Possible Side Effects and Safety Information

The official safety profile for Prednisolone Acetate ophthalmic suspension is predominantly defined by risks associated with duration of exposure, as documented in regulatory sources such as the FDA and SmPC.


Ocular and Systemic Adverse Reactions

Adverse reactions are classified primarily within Eye Disorders, though effects in the Nervous System, Skin, and Immune System are also officially documented. Major ocular risks are typically listed in decreasing order of frequency in the FDA label or classified as Not Known in post-marketing reports.

  • Major Ocular Risks (Associated with Prolonged Use): The most significant potential adverse reactions are the development of glaucoma with optic nerve damage due to sustained elevation of intraocular pressure (IOP), and the formation of posterior subcapsular cataract. These effects are officially linked to prolonged or long-term use of the corticosteroid.
  • Secondary Effects: The drug is associated with a risk of secondary ocular infection (bacterial, viral, or fungal), as the steroid can potentially mask or enhance existing infections. Perforation of the globe is a documented risk when the medication is used in the presence of existing thinning of the cornea or sclera.
  • Other Documented Effects: Other officially reported reactions include transient burning and stinging upon instillation, ocular irritation, headache, rash, and hypersensitivity reactions.

Population-Specific and Time-Related Safety

Systemic hypercorticoidism or adrenal suppression is a rare but documented systemic risk, with regulatory documents noting that pediatric patients may be at a higher risk with prolonged, high-dose use compared to adults. The medication is officially not recommended during lactation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory prescribing information for Prednisolone Acetate Ophthalmic Suspension indicates that acute overdosage will not ordinarily cause acute systemic problems when administered via the intended ocular route. Due to the low systemic absorption of this topical corticosteroid, acute systemic toxicity is not typically expected.


Required Emergency Actions

The primary concern requiring immediate action is accidental oral ingestion of the suspension. The regulatory guidance is explicit:

  • Seek emergency medical attention or contact a Poison Help center immediately if the medication is accidentally swallowed.
  • If accidental ingestion occurs, the officially described supportive action is to drink fluids to dilute the product.
  • If there is over-exposure to the eye, the required initial action is to rinse the eye thoroughly with water.

Overdose Management and Specific Risks

Treatment for overdose is generally described as symptomatic and supportive, as no specific antidote is known for Prednisolone Acetate.

Regulatory documents also note a population-specific risk related to prolonged use, distinguishing it from acute overdose: the risk of adrenal suppression must be considered for infants and children receiving frequent, high-dose therapy over an extended period. Otherwise, no severe, life-threatening acute outcomes are documented for the ophthalmic product.

Therapeutic Uses of Pred-Forte

This medication is generally used to provide support for inflammatory states in the eye, applied within therapeutic areas involving inflammatory processes. It is used in contexts where additional symptomatic support is needed to address symptoms related to inflammatory states.

It is generally used across conditions characterized by periods of heightened symptoms, such as certain types of uveitis, iritis, and keratitis, and is relevant when supportive symptom management is appropriate, applied in scenarios where symptoms escalate temporarily following certain eye surgeries (e.g., cataract removal). This support helps address symptom clusters that may become intense or disruptive.

“The application is relevant for easing disruptive manifestations and providing symptomatic relief.”

The medication is relevant for easing the impact of symptoms that interfere with daily comfort, including pain, soreness, and sensitivity to light (photophobia). This assistance contributes to day-to-day comfort during periods of heightened symptoms and may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Contexts Involving Inflammatory Symptoms Pred-Forte is commonly used in scenarios where symptoms escalate temporarily following surgery and for conditions like iritis, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

Regulatory References

  1. NIH DailyMed product information

Eligibility and Restrictions for Use

Who Can and Cannot Use Pred-Forte?

Eligibility for Pred-Forte (prednisolone acetate ophthalmic suspension) is strictly governed by regulatory labeling, primarily concerning existing infections and patient age.

Contraindicated Populations (Must Not Use)

Official labeling contraindicates use in patients with specific ocular infections or known hypersensitivity to any ingredient. These include individuals with epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infection of the eye, fungal diseases of ocular structures, or acute untreated purulent infections.

Conditional Use and Restrictions

Use requires great caution in certain populations. Patients with glaucoma or a history of ocular herpes simplex must be closely monitored. Use in pregnant or lactating individuals is conditional, permitted only if the potential benefit justifies the potential risk to the fetus or infant, as determined by a healthcare professional.

Age-Based Eligibility

Use is established for adults and older adults. While safety and efficacy have been established in pediatric patients under U.S. regulatory standards, some international labeling states that safety and efficacy have not yet been established for children, restricting its use in those regions.

What should I know about interactions with other medicines?

The systemic absorption of Pred-Forte (prednisolone acetate ophthalmic suspension) is minimal following topical ocular administration; however, a potential for drug-drug interaction exists when used concurrently with certain systemic medications.

Drug Interactions

Interacting Agents Interaction Mechanism / Result Monitoring / Constraint
CYP3A Inhibitors (e.g., Ritonavir, Cobicistat) These agents may inhibit the metabolism of prednisolone, potentially increasing the systemic exposure of the corticosteroid. Co-treatment requires careful monitoring for systemic corticosteroid side effects, including adrenal suppression.
Other Ophthalmic Corticosteroids Concurrent use may lead to additive effects and an increased risk of local side effects, particularly with prolonged use. Use with caution and only under strict supervision; careful monitoring for ocular adverse events is required.

Product-Related Constraint

Pred-Forte contains benzalkonium chloride, a preservative which can be absorbed by soft contact lenses and cause lens discoloration. Patients who wear soft contact lenses are advised to remove the lenses prior to administration of the eye drops. Lenses may be safely reinserted 15 minutes after the drops have been instilled. This is a procedural constraint related to the excipient, not the active ingredient.

Mechanism of Action

Prednisolone acetate, upon cellular entry, is converted by ester hydrolysis to its active form, prednisolone. Prednisolone functions as an agonist for the cytoplasmic glucocorticoid receptor ( GR). The ligand-receptor complex subsequently translocates into the cell nucleus.

Within the nucleus, the activated GR complex modulates gene transcription by binding to glucocorticoid response elements ( GREs) on the DNA. This action results in the transrepression of genes encoding pro-inflammatory mediators, such as cyclooxygenase-2 ( COX-2), various cytokines ( IL-1, IL-6, TNF-alpha), and chemokines ( IL-8). Simultaneously, it causes the transactivation of genes for anti-inflammatory proteins, notably lipocortin-1 (annexin A1).

The resulting increase in lipocortin-1 inhibits the enzyme phospholipase A2 ( PLA2), thereby reducing the release of arachidonic acid from cell membrane phospholipids. This downstream cascade constrains the biosynthesis of prostaglandins and leukotrienes.

System-level physiological modulation is characterized by reduced capillary permeability, decreased fibrin deposition, and suppressed leukocyte migration and proliferation, directly modulating the complex cellular and vascular processes inherent to the affected tissues.

Dosage and Administration Information

Administration of Pred-Forte Ophthalmic Suspension

Pred-Forte (prednisolone acetate ophthalmic suspension) is strictly for ocular instillation into the conjunctival sac. As a suspension, the bottle must be shaken well immediately before each use to ensure the dose is consistent.

Dosing and Frequency

Age Group Standard Dose and Frequency Special Conditions
Adults & Elderly Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the frequency may be increased to 2 drops every hour, if necessary.
Pediatrics Safety and efficacy have not been established (use in children under 18 is not recommended). Consult a specialist.

Procedural Steps

  1. Wash hands thoroughly.
  2. Shake the bottle well.
  3. Tilt the head back, look upward, and pull down the lower eyelid to create a pouch.
  4. Hold the dropper tip close to the eye without touching it, and instill the prescribed one or two drops into the pouch.
  5. Immediately following instillation, close the eye gently and apply light pressure to the inner corner of the eye (punctal occlusion) for 1 minute to help reduce possible systemic absorption.
  6. Replace the cap securely.

Special Instructions

Soft contact lenses must be removed prior to administration, as the preservative may be absorbed; they may be reinserted after 15 minutes. If a dose is missed, instill the drop as soon as remembered, but do not double the dose to make up for the missed one. Therapy should not be discontinued prematurely, and a physician should re-evaluate the patient if symptoms fail to improve within 2 days. The product is generally not recommended for use beyond 10 days unless under strict ophthalmic supervision.

Recent Clinical Evidence

Research evidence / Overview of studies for Pred-Forte


Evidence for Use Following Eye Surgery (Post-Operative Inflammation)

The research base supporting the study of Prednisolone Acetate Ophthalmic Suspension in the period following eye surgery, such as cataract removal, is derived from short-term, randomized controlled trials (RCTs). These studies were generally applied in research contexts involving adult patients undergoing standard surgical procedures. Researchers focused on tracking objective clinical signs of inflammation, measured by grading cell and protein presence in the front chamber of the eye (AC Cell and AC Flare scores). Studies also monitored patient-reported outcomes describing perceived discomfort.

Research highlights changes measured during the study period in the main signs of inflammation. Trials described patterns observed in the studies related to the resolution of AC cell and flare measurements in studies that included comparisons against an inactive substance or other pharmacological agents. Findings describe group patterns, indicating that the medication was studied for its ability to track these objective measures of inflammation in the immediate post-operative phase.

Evidence for Use in Anterior Uveitis and Iritis

The research base for this medicine in inflammatory conditions like anterior uveitis and iritis is comprised of Randomized Controlled Trials (RCTs), where the drug was evaluated in studies designed to compare it with other topical steroid treatments. Studies monitored outcomes linked to inflammatory or irritative states, focusing specifically on the resolution of AC cell and flare measurements over defined time intervals. The study populations primarily included adult patients.

What Research Gaps and Uncertainties Remain

Despite the body of short-term data, long-term effects are not fully established. Follow-up durations were limited in the most definitive efficacy trials, meaning limited information for long-term outcomes is available. Comparative evidence is lacking for several specific indications, and subgroup findings are uncertain due to modest sample sizes. Evidence for the use in pediatric patients (children) is limited, and findings for this group are often based on an extrapolation of data from adult studies.

Frequently Asked Questions (FAQ)

Common questions about Pred-Forte (FAQ)


Q: What kind of eye issues is Pred-Forte typically used for?

A: Official documents state that this medication is indicated for treating inflammation in various parts of the eye. Specifically, it is used for steroid-responsive inflammation affecting the palpebral (eyelid lining) and bulbar conjunctiva, the cornea, and the anterior segment of the globe.


Q: What are the most commonly reported side effects people ask about?

A: The official product information reports that major risks associated with prolonged use are the elevation of pressure inside the eye, which can potentially lead to glaucoma, and the formation of posterior subcapsular cataracts. Other minor effects that are often reported include a transient burning or stinging sensation right after using the drops, as well as headache and rash.


Q: What are the general expectations for eye redness improvement after starting Pred-Forte?

A: The prednisolone acetate active ingredient is known to be absorbed into the cornea rapidly. Official administration guidelines allow the dosage frequency to be increased during the initial 24 to 48 hours for acute inflammation. This indicates that, based on guidelines for acute inflammation, the beginning of the anti-inflammatory effect is often addressed within this early period, though individual results may vary.


Q: Does Pred-Forte affect blood pressure or blood sugar levels?

A: Because this is a topical eye drop, the amount of medicine absorbed into the rest of the body is minimal. However, regulatory warnings acknowledge the potential for mild systemic side effects to occur in rare instances of very prolonged or high-dose use. These potential effects include reported instances of increased blood pressure or blood sugar levels.


Q: Can Pred-Forte be used for seasonal allergies in the eye?

A: Yes, the official indications for this product cover inflammation of the eye that responds to steroids. This general category includes inflammatory conditions caused by allergies, such as severe seasonal eye allergies.


Q: What is the difference between the 'Forte' version and a standard Prednisolone drop?

A: The brand name Pred Forte is supplied as a 1% ophthalmic suspension that is specifically formulated as a sterile micro-fine suspension. This unique particle size and formulation are designed for high uniformity and sustained contact with the eye surface compared to some standard or generic prednisolone preparations.


Q: Is Pred-Forte the same thing as generic prednisolone eye drops?

A: Pred-Forte and generic prednisolone eye drops contain the same active ingredient. However, official information highlights that the trade name product uses a micro-fine suspension technology, which is designed for uniformity and sustained contact with the eye surface. Differences in formulation, such as particle size, may sometimes lead to variability in performance compared to the generic product.


Q: How long does it usually take for Pred-Forte to start working?

A: The official pharmacokinetic data shows that the maximum measurable concentration of the active ingredient in the aqueous humour (the front part of the eye) is typically reached between 30 and 45 minutes after use. This measurable concentration indicates the drug's presence at the target site.


Q: Are there different strengths of Pred-Forte available?

A: The Pred Forte trade name product is consistently supplied as a 1% concentration (10 mg/mL) of prednisolone acetate ophthalmic suspension. Other strengths of prednisolone acetate products are available under different brand names or as generics, but are not typically marketed under the Pred Forte name.


Q: Can Pred-Forte make my eyes more sensitive to light?

A: Sensitivity of the eye to light (photophobia) is listed as a reported adverse reaction in the official product safety information. While this symptom has been documented, official sources indicate that the frequency or incidence rate for this side effect is not known.


Q: Are there any specific activities or machines I should avoid while using Pred-Forte?

A: Because temporary blurred vision is a reported adverse reaction, caution is advised if you experience visual disturbances immediately after instilling the drops. If vision is affected, exercising caution when driving or operating machinery is generally advised until the sight clears.


Q: Does Pred-Forte cause dry eyes, or can it help with dryness?

A: Dry eyes and ocular irritation are among the potential adverse reactions officially documented for this ophthalmic suspension. The medication is indicated for treating inflammation, not specifically dryness, and dryness may be a documented side effect, although the incidence rate is not known.


Q: Why is it important not to share Pred-Forte eye drops with others?

A: Official patient information emphasizes that each bottle is intended for use by one individual only. Sharing the medicine is generally not advised, as it may lead to cross-contamination and the potential spread of eye infection between people.


Q: What is the risk of rebound inflammation after stopping Pred-Forte?

A: Regulatory guidance strongly advises that therapy with prednisolone eye drops should not be discontinued prematurely. This official precaution is related to the possibility of symptoms worsening or returning if the treatment is stopped too soon before the inflammation is fully controlled.


Q: How quickly do the effects of Pred-Forte wear off after stopping the medication?

A: Pharmacokinetic studies show that the active ingredient, prednisolone acetate, has a relatively short presence in the eye's aqueous humour. The half-life, which is the time it takes for the concentration to reduce by half, is approximately 30 minutes.

How should Pred-Forte be stored and disposed of?

Storage and Disposal of Pred-Forte

Official regulatory documents define specific requirements for the storage, handling, and disposal of Pred-Forte (prednisolone acetate ophthalmic suspension).


Storage Conditions

  • Temperature: Store at controlled room temperature, up to 25°C (77°F).
  • Freezing: The product must be protected from freezing.
  • Container: The bottle must be kept tightly closed and stored in an upright position.
  • Child Safety: Keep this medicine out of the reach of children.

Stability and Disposal

  • In-Use Life: The suspension must be discarded 28 days after the date of first opening.
  • Disposal: Unused or expired medicine must not be thrown into household waste or flushed into wastewater.
  • Method: Return unused product to a pharmacist for safe, proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pred-Forte found in:

A-Z Index: